Mecasermin
- Generic Name
- Mecasermin
- Brand Names
- Increlex
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 68562-41-4
- Unique Ingredient Identifier
- 7GR9I2683O
- Background
Mecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1). IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. The amino acid sequence of the product is identical to that of endogenous human IGF-1. The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1.
- Indication
For the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH . It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy.
- Associated Conditions
- Primary Insulin-like Growth Factor-1 Deficiency
- Associated Therapies
- -
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
- Conditions
- Growth FailureX-linked Severe Combined Immunodeficiency (XSCID)Growth Hormone Resistence
- Interventions
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2015-07-03
- Target Recruit Count
- 6
- Registration Number
- NCT00490100
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.